Inhibition of cerebral vascular inflammation by brain endothelium-targeted oligodeoxynucleotide complex

Neuroscience. 2016 Aug 4:329:30-42. doi: 10.1016/j.neuroscience.2016.04.033. Epub 2016 Apr 27.

Abstract

The present study generated a novel DNA complex to specifically target endothelial NF-κB to inhibit cerebral vascular inflammation. This DNA complex (GS24-NFκB) contains a DNA decoy which inhibits NF-κB activity, and a DNA aptamer (GS-24), a ligand of transferrin receptor (TfR), which allows for targeted delivery of the DNA decoy into cells. The results indicate that GS24-NFκB was successfully delivered into a murine brain-derived endothelial cell line, bEND5, and inhibited inflammatory responses induced by tumor necrosis factor α (TNF-α) or oxygen-glucose deprivation/re-oxygenation (OGD/R) via down-regulation of the nuclear NF-κB subunit, p65, as well as its downstream inflammatory cytokines, inter-cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule (VCAM-1). The inhibitory effect of the GS24-NFκB was demonstrated by a significant reduction in TNF-α or OGD/R induced monocyte adhesion to the bEND5 cells after GS24-NFκB treatment. Intravenous (i.v.) injection of GS24-'NFκB (15mg/kg) was able to inhibit the levels of phoseph-p65 and VCAM-1 in brain endothelial cells in a mouse lipopolysaccharide (LPS)-induced inflammatory model in vivo. In conclusion, our approach using DNA nanotechnology for DNA decoy delivery could potentially be utilized for inhibition of inflammation in ischemic stroke and other neuro-inflammatory diseases affecting cerebral vasculature.

Keywords: NF-κB; aptamer; endothelial cells; inflammation; lipopolysaccharide; oxygen-glucose deprivation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / blood
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / pharmacology*
  • Aptamers, Nucleotide / blood
  • Aptamers, Nucleotide / pharmacokinetics
  • Aptamers, Nucleotide / pharmacology*
  • Brain / blood supply
  • Brain / drug effects*
  • Brain / immunology
  • Cell Hypoxia / drug effects
  • Cell Line
  • Disease Models, Animal
  • Drug Design
  • Drug Evaluation, Preclinical
  • Endothelial Cells / drug effects*
  • Endothelial Cells / immunology
  • Glucose / deficiency
  • Goats
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Lipopolysaccharides
  • Male
  • Mice
  • Neuroprotective Agents / blood
  • Neuroprotective Agents / pharmacokinetics
  • Neuroprotective Agents / pharmacology
  • Oligodeoxyribonucleotides / blood
  • Oligodeoxyribonucleotides / pharmacokinetics
  • Oligodeoxyribonucleotides / pharmacology*
  • Tumor Necrosis Factor-alpha
  • Vasculitis, Central Nervous System / drug therapy*
  • Vasculitis, Central Nervous System / metabolism

Substances

  • Anti-Inflammatory Agents
  • Aptamers, Nucleotide
  • Lipopolysaccharides
  • Neuroprotective Agents
  • Oligodeoxyribonucleotides
  • Tumor Necrosis Factor-alpha
  • Glucose